Melatonin alleviates vascular endothelial cell damage by regulating an autophagy-apoptosis axis in Kawasaki disease

Yuanzheng Zheng1,2 | Saihua Huang2,3 | Jialing Zhang1,2 | Jia Hou4 |
Fang Wu5 | Wenji Wang1,2 | Xiao Han2,3 | Yonghao Gui1,2

1Cardiovascular Center, Children's Hospital of Fudan University, Shanghai, China
2National Health Commission (NHC) Key Laboratory of Neonatal Diseases, Fudan University, Shanghai, China
3Institute of Pediatrics, Children's Hospital of Fudan University, National Children's Medical Center, Fudan University, Shanghai, China
4Department of Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China
5Department of Neonatology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence
Xiao Han and Yonghao Gui, National Health Commission (NHC) Key Laboratory of Neonatal Diseases, Fudan University, 399 Wanyuan Road, Minhang, Shanghai, 201102, China.
Email: sqhx12@126.com and yhgui_sh@163.com

Funding Information
Fudan University, Grant/Award Numbers: 2019DGJFYJK01, 2020DGJFYJK01, 2021DGJFYJK01; Fudan University Original project, Grant/Award Number: IDF156012/001; National Natural Science Foundation of China, Grant/Award Number: 81900751; Shanghai Committee of Science and Technology, Grant/Award Number: 20ZR1408300

Abstract

Objectives: Melatonin has been reported to be an appropriate candidate for mitigating various cardiovascular injuries, owing to its versatility. This study aimed to explore the role of melatonin in Kawasaki disease (KD)-associated vasculitis and its underlying mechanisms.

Material and Methods: The role of melatonin was evaluated in human coronary artery endothelial cells (HCAECs), peripheral blood mononuclear cells from KD patients, human THP1 cell line in vitro, and a Candida albicans water-soluble fraction (CAWS)-induced KD mouse model in vivo. Cell proliferation assay, cell apoptosis assay, cell co-culture, RNA extraction, RNA sequencing, reverse transcription quantitative PCR, enzyme-linked immunosorbent assay (ELISA), transwell assay, western blot, dual-luciferase reporter assay, and autophagic flux assay were performed to investigate the function and regulatory mechanisms of melatonin in vitro, while haematoxylin and eosin staining, Verhoeff's van Gieson staining, ELISA, and immunohistochemical analysis were performed to detect the effect of melatonin in vivo.

Results: Melatonin suppressed cell apoptosis directly reduced the expression of endothelial cell damage markers in HCAECs, and alleviated vasculitis in the CAWS-induced KD mouse model. Mechanistically, melatonin promoted autophagy by activating the melatonin/ melatonin receptor (MT)/cAMP-response element binding protein (CREB) pathway and upregulating the expression of autophagy-related gene-3, thereby suppressing cell apoptosis in an autophagy-dependent manner. Additionally, melatonin decreased the production of pro-inflammatory cytokines in macrophages and indirectly reduced the immunopathological damage of HCAECs.

Conclusions: This study revealed that melatonin protects vascular endothelial cells in KD, by suppressing cell apoptosis in an autophagy-dependent manner and reducing the immunopathological damage mediated by macrophages.
1 | INTRODUCTION

Kawasaki disease (KD) is one of the most common childhood vasculitides that predominantly affects children younger than 5 years of age, and is the leading cause of childhood-acquired heart disease in developed countries.1–4 Coronary artery aneurysms (CAAs) are one of the most lethal complications of KD. Despite four decades of investigation, the cause and pathogenesis of KD remain unclear, and current evidence suggests that genetics, inflammation, and autoimmunity may be responsible for the occurrence of the disease.5 Although timely treatment with intravenous immunoglobulin (IVIG), which is regarded as the mainstay therapy, has been shown to reduce the incidence of CAA,6 a considerable number of patients do not respond to IVIG therapy, which places them at an increased risk of coronary complications.7 In addition, other approaches, including a second round of IVIG, glucocorticoid steroids,8 infliximab, etc., have also not been found to substantially reduce the residual risk of CAA.6 Therefore, there is an urgent need to explore additional therapies to reduce the incidence of CAA in KD, and to alleviate the burden of the disease.

Melatonin (N-acetyl-5-methoxytryptamine) is an endogenous chemical hormone that is mainly synthesized in the pineal gland and released into the circulation following a circadian rhythm. Melatonin functions in diverse ways and presents a wide spectrum of physiological and pathophysiological effects, such as regulation of circadian rhythms,9 immune regulation,10 antioxidant,11 and prevention of cancer metastasis.12 Generally, melatonin functions by binding to the G protein-coupled receptors (GPCRs) MT1 and MT2 (melatonin receptor 1 and 2), both of which are expressed in almost all nucleate cells.13 GPCRs play an important pathophysiological role in the occurrence and development of diseases through their interaction with downstream signal transduction molecules. Melatonin has been reported to protect against cardiovascular disease-mediated myocardial damage, including ischemia/reperfusion,14 atherosclerosis,15 hypertension,16,17 and thoracic aortic aneurysm and dissection.11 However, the role of melatonin in KD remains unclear.

Autophagy is an essential process for degrading misfolded proteins or damaged organelles, to maintain cellular homeostasis.18 With the help of a series of dynamic membrane-rearrangement reactions mediated by autophagy-related gene (ATG) products,19 unnecessary cellular components, including misfolded proteins, damaged organelles, and invading pathogens, are delivered to the lysosome by double-membraned vesicles called autophagosomes, for degradation.19 Accumulating evidence suggests that increased autophagy attenuates vasculitis in various cardiovascular diseases.20,21 Intriguingly, studies have shown that some existing modality therapies may attenuate KD via the induction of autophagy. Huang et al. demonstrated that the mRNA levels of autophagy markers including microtubule-associated protein 1 light chain (LC3)β, BECLIN1, and ATG16L1 were downregulated in the white blood cells of children with KD, but these increased significantly after IVIG therapy.22 Another study showed that resveratrol may improve the inflammatory response of coronary arteries in KD, by exerting anti-inflammatory effects on human coronary artery endothelial cells (HCAECs), via induction of autophagy.23

Apoptosis is the predominant form of programmed cell death. Physiological apoptosis aids in maintaining cellular homeostasis, whereas pathological apoptosis leads to diseases. Autophagy and apoptosis control the turnover of cellular proteins and organelles, and the two are generally negatively correlated. Autophagy promotes cell survival and blocks apoptosis. However, autophagy has also been reported to promote apoptosis in some specific conditions, such as tumours.24,25 Autophagy and apoptosis interact with each other by sharing some proteins, such as the Beclin1/B-cell lymphoma-2 (Bcl-2) complex. Beclin 1 is an essential protein that regulates autophagy by interacting with the anti-apoptotic protein Bcl-2.25,26 Apoptosis caused by excessive immune activation and oxidative stress leads to vascular injury in KD patients,27,28 while autophagy has been shown to protect endothelial cells by attenuating inflammation in a KD mouse model.21 Nevertheless, the role of the interaction between endothelial cell autophagy and apoptosis in the pathogenesis of KD remains uncertain.

Considering the protective roles of melatonin and autophagy in a series of cardiovascular and autoimmunity diseases,29 in the present study, we aimed to investigate the function of melatonin in the vasculitides of KD and determine whether the underlying mechanism is autophagy-dependent.

2 | MATERIAL AND METHODS

2.1 | Human subjects

A total of 16 patients diagnosed with KD (10 boys and 6 girls; mean age = 2.9 years) were recruited between July 2020 and October 2020, from the Cardiovascular Center of Children’s Hospital of Fudan University, Shanghai, China. KD diagnosis was based on the guidelines released by the American Heart Association6 and the Japanese Circulation Society.30,31 The flow chart of KD patient selection process is shown in Figure S1. Peripheral blood mononuclear cells (PBMCs) from these patients were isolated using Ficoll-Paque density gradient solution (GE Healthcare, USA). Briefly, peripheral blood was centrifuged at 400 g for 10 min, to separate the supernatant serum, while the sedimented blood cells were mixed with phosphate-buffered saline (PBS) and overlaid on top of Ficoll. Post centrifugation at 400 g for 30 min, the PBMCs were aspirated from the intermediate interface. The cell pellet was washed twice with PBS, and the CD14+ cells obtained from the PBMCs were sorted using a magnetic cell sorting system (Miltenyi Biotec, Germany) and then cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco, USA) containing 10% fetal bovine serum (FBS; Gibco), 1% penicillin/streptomycin (Gibco), and 10 ng/ml recombinant human macrophage colony-stimulating factor-1 (rhM-CSF, R&D Systems, USA) for 7 days, to generate the macrophages. The macrophages were then stimulated with 100 ng/ml lipopolysaccharide (LPS, Sigma-Aldrich, USA) or 20 ng/ml recombinant...
human tumour necrosis factor-α (TNF-α, R&D Systems), with or without 0.5 mM melatonin (Sigma-Aldrich) pre-treatment.

Written informed consent was obtained from all the participants. The study was approved by the Research Ethics Board of the Children’s Hospital of Fudan University (IRB protocol number: 2019-328). The inclusion criteria for KD patients in this study were as follows: (i) fulfilled the diagnostic criteria of the guidelines released by the Japanese Circulation Society \(^\text{30,31}\) and American Heart Association \(^\text{6}\); (ii) were in the timeframe of within 5–10 days of illness and had not yet been treated with IVIG, aspirin, steroids, or immunosuppressive drugs; and (iii) the patients and their guardians voluntarily participated in this study and signed the informed consent form. The exclusion criteria for KD patients in this study were as follows: (i) did not fulfil the inclusion criteria; (ii) had a previous history of KD; (iii) had severe concomitant medical disorders; and (iv) did not have samples available for collection. Blood samples were collected on the day of admission prior to the administration of IVIG, aspirin, steroids, or immunosuppressive drugs. The general patient information is listed in Table S1. The time of sample collection, treatment, and representative laboratory data before IVIG treatment are shown in Table S2. The urinary levels of 6-sulfatoxymelatonin in the patients are shown in Table S3.

2.2 | Cell culture, stimulation, and transfection

HCAECs were purchased from ScienCell Research Laboratories (USA) and cultured in flasks coated with fibronectin (2 μg/cm²), in a humidified atmosphere containing 5% CO₂ at 37°C. The medium was an endothelial cell medium (ECM, ScienCell) containing 1% endothelial cell growth supplement, 5% FBS, and 1% penicillin/streptomycin. To investigate the effect of melatonin, the cells were incubated in ECM containing 0.5 mM melatonin for 6 h, and then stimulated with 20 ng/ml TNF-α for different time points. Transient transfections of small interfering RNAs (siRNAs; GenePharma, China) were performed using Lipofectamine® RNAiMAX reagent (Invitrogen, USA), while those of plasmids were performed using Lipofectamine® 2000 (Invitrogen), according to standard procedures. The sequences of the siRNAs are listed in Table S4.

The human THP1 cell line was obtained from American Type Culture Collection (USA) and maintained in RPMI-1640 medium with inactivated 10% FBS and 1% penicillin-streptomycin. THP1 cells were induced into macrophages with 200 ng/ml phorbol 12-myristate 13-acetate (Sigma-Aldrich) for 48 h. LPS (100 ng/ml) or TNF-α (20 ng/ml) was then used to induce macrophage activation, with or without 0.5 mM melatonin (Sigma-Aldrich) pre-treatment.

2.3 | Co-culture of HCAECs and THP1 cells

After stimulation with LPS (100 ng/ml), the culture supernatant of the THP1-derived macrophages, with or without melatonin pre-treatment, was collected and centrifuged for 30 min at 3000 rpm, 4°C, to remove the cell debris. After HCAECs were seeded into 6-well or 96-well cell culture plates for 24 h, the ECM medium was replaced with a mixed conditional medium containing a 3:1 volume ratio of ECM to THP1 culture supernatant. Cell proliferation and apoptosis were detected at the designated time-points.

2.4 | Cell proliferation assay

Cell proliferation was detected using the Cell Counting Kit-8 (CCK8) Assay Kit (Dojindo, Japan), according to the manufacturer’s instructions. Briefly, HCAECs were seeded into 96-well plates at a density of 2000 cells/well. After the corresponding treatment, cell viability was detected at the designated time-points (0, 24, 48, and 72 h), by adding 10 μl CCK8 solution to the cells and incubating for 2 h at 37°C. The absorbance at 450 nm was measured using a microplate reader (BioTek, USA).

2.5 | Cell apoptosis assay

Apoptosis was examined using an Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double-staining kit (BD Biosciences, USA), following the manufacturer’s protocol. HCAECs were cultured into 6-well plates (2 × 10⁵ cells/well) for 48 h. After melatonin and TNF-α treatment, the cells were digested with ethylenediaminetetraacetic acid (EDTA)-free trypsin. Next, the cells were stained with FITC and PI, and subjected to flow cytometry using FACSCanto™ II (BD Biosciences). The data were analysed using FlowJo V10 software (Tree Star, USA).

2.6 | RNA extraction and reverse transcription quantitative PCR (RT-qPCR)

Total RNA was extracted from the cells using TRIzol® reagent (Invitrogen) and reverse transcribed into complementary DNA (cDNA) using the PrimeScript RT Reagent Kit (Takara Bio) on a Roche 480 Real Time PCR System (Roche, Switzerland). β-actin was used as an internal reference, and the relative expression was calculated using the 2⁻ΔΔCT method. The primer sequences used in this study are provided in Table S5.

2.7 | Transwell assay

THP1-derived macrophages were added to the top chamber of polycarbonate Transwells (Corning, USA), while HCAECs (pre-treated with or without 0.5 mM melatonin) were seeded in the bottom chamber and stimulated with 20 ng/ml TNF-α. After co-culturing for 24 h in a 5% CO₂-containing atmosphere at 37°C, the macrophages on the upper membrane surface were wiped gently with cotton swabs and washed with cold PBS. Cells on the underside of the membrane were fixed with 4% paraformaldehyde and stained with Crystal Violet. Next, the number...
of migrated macrophages on the membrane underside was counted using a microscope (Leica, Germany), in five random fields.

2.8 | Western blot

Proteins from cells lysed in radioimmunoprecipitation assay buffer containing protease inhibitors were quantified using a bicinchoninic acid protein assay kit (Beyotime, China) and then denatured at 100°C for 10 min. Proteins (15 μg/lane) were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Cleaved caspase-9, Bcl-2, β-actin, protein kinase B (AKT), phosphorylated AKT (p-AKT), and p62 were separated using 10% SDS-PAGE; cleaved caspase-3, LC3-I, and LC3-II were separated using 12% SDS-PAGE; mammalian target of rapamycin (mTOR) and phosphorylated mTOR (p-mTOR) proteins were separated using 8% SDS-PAGE. The proteins were then transferred onto polyvinylidene difluoride membranes (Bio-Rad, USA), and blocked with 5% bovine serum albumin (BSA, Bio-Rad) in Tris-buffered saline (TBS, Bio-Rad) with 0.1% Tween-20 (Sigma-Aldrich). The membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (1:2000, ProteinTech, USA) for 1 h at room temperature. An enhanced chemiluminescent western blotting substrate kit (Promega, USA) and measurement of the concentration and purity of a Qubit® 3.0 Fluorometer (Life Technologies, USA) and NanoDrop™ One spectrophotometer (Thermo Fisher Scientific). Next, the samples were sequenced using next-generation sequencing on an Illumina sequencing platform (Novaseq 6000, Illumina, USA). After sequencing, the filtered high-quality sequences (clean data) filtered from the original raw data were mapped to the Homo sapiens GRCh38 genome. Based on the mapped results, the expression level of each gene was calculated, and the samples of the control and melatonin groups were subjected to further analysis such as expression difference, enrichment, and cluster analysis. Genes with p ≤ 0.05 and |fold change| ≥ 2.0 were considered significantly differentially expressed. The data referred to in this study have been deposited in Gene Expression Omnibus database, with the accession number GSE183359.

2.11 | RNA sequencing (RNA-seq)

HCAEs stimulated with TNF-α (20 ng/ml), with or without melatonin (0.5 mM) pre-treatment, were prepared for RNA-seq (Sinotech Genomics, China). RNA extraction was performed, followed by the assessment of integrity using an Agilent Bioanalyzer 2100 (Agilent Technologies, USA), and measurement of the concentration and purity using a Qubit® 3.0 Fluorometer (Life Technologies, USA) and NanoDrop™ One spectrophotometer (Thermo Fisher Scientific). Next, the samples were sequenced using next-generation sequencing on an Illumina sequencing platform (Novaseq 6000, Illumina, USA). After sequencing, the filtered high-quality sequences (clean data) filtered from the original raw data were mapped to the Homo sapiens GRCh38 genome. Based on the mapped results, the expression level of each gene was calculated, and the samples of the control and melatonin groups were subjected to further analysis such as expression difference, enrichment, and cluster analysis. Genes with p ≤ 0.05 and |fold change| ≥ 2.0 were considered significantly differentially expressed. The data referred to in this study have been deposited in Gene Expression Omnibus database, with the accession number GSE183359.

2.12 | Plasmid construction

The full-length cAMP-response element binding protein (CREB) coding DNA sequence (CDS) was inserted into the blank pCMV-C-Flag plasmid at HindIII and XbaI restriction sites, to construct the CREB-CDS vector. The ATG3 promoter sequence containing CERB binding sites was inserted into the pGL3-basic plasmid at Nhel and Xhol restriction sites, to generate the ATG3-promoter plasmid. The pRL-Tk Renilla plasmid was purchased from Tsingke Biological (China). The primer pairs for the amplification of full-length CREB and ATG3 promoters are provided in Table S6.

2.13 | Dual-luciferase reporter assay

293 T cells were seeded into 96-well plates, followed by co-transfection of CREB-CDS, ATG3-promoter, and Renilla plasmids using Lipofectamine™ 2000 transfection reagent, according to the manufacturer’s protocol. After 48 h, the luciferase activity in the cells was analysed using the Dual-Luciferase® Reporter Assay System (Promega, USA).
2.14 Preparation of *Candida albicans* water-soluble fraction (CAWS)

CAWS was prepared from *C. albicans* strain NBRC1358 (NITE Biolog-
cal Resource Center, Japan), as previously described. Briefly, *C. albicans* was cultured in C-limiting medium at 400 rpm, 27°C, for 48 h. Following culture, an equal volume of ethanol was added, and the mixture was incubated overnight. The precipitate was then collected, dissolved in 250 ml of distilled water, and an equal volume of ethanol was added to it. This mixture was left to stand overnight, following which the precipitate was collected and dried with acetone to obtain CAWS.

**FIGURE 1** Legend on next page.
2.15 | CAWS-induced KD mouse model and animal grouping

All experimental procedures were approved by the Local Ethics Committee of the Children’s Hospital of Fudan University, and all animals received humane care, according to the Guidelines for Ethical Care of Experimental Animals of Children’s Hospital of Fudan University. C57BL/6 wild-type mice (4 weeks of age, male) were purchased from SLAC Laboratory Animal Co. Ltd. (China) and maintained in a specific pathogen-free room at 22 ± 2 °C, with automatic light cycles (12/12 h light/darkness) and 50% humidity.

The mice were divided into three equal experimental groups (16 mice/group). Mice in the PBS group were intraperitoneally (i.p.) injected with 0.1 ml PBS for 30 days, from day −2; mice in the CAWS group received an i.p. dose of 8 mg CAWS daily, for 5 consecutive days, from day 0; and mice in the CAWS + melatonin group received 8 mg i.p. CAWS, daily for 5 consecutive days, from day 0, as well as, i.p. melatonin for 30 days, from day −2. Melatonin (dissolved in absolute ethanol and diluted with PBS before use) was administered at a dose of 40 mg/kg/day. Mice (n=8) in each group were anaesthetized and sacrificed on days 14 and 28, following which their blood samples were collected. The sample sera were separated by means of centrifugation at 2000 rpm for 10 min, and then stored at −80 °C until analysis. Part of the heart and abdominal aorta tissues were isolated and immediately frozen in liquid nitrogen until required for molecular biology experiments, while the rest were fixed with 4% paraformaldehyde for pathological examination.

For the construction of the Atg3-knockdown mouse model, C57BL/6 wild-type mice (4 weeks of age, male) were infected with a lentivirus vector carrying short hairpin RNA (shRNA; GenePharma), according to the manufacturer's instructions. Mice in the si-Atg3−−CAWS+/+melatonin group received 5 × 10^7 transducing units (TU) of si-Atg3 lentivirus by means of tail intravenous injection on day −3, followed by 8 mg i.p. CAWS, for 5 consecutive days, from day 0, as well as, i.p. melatonin, for 30 days, from day −2. Meanwhile, mice in the negative control group (si-NC+/−CAWS+/+melatonin) received 5 × 10^7 TU of negative control lentivirus, with the administration of CAWS and melatonin being the same as that in the si-Atg3−−CAWS+/+melatonin group. The sequences of shRNAs carried by the lentivirus are listed in Table S7.

2.16 | Histological analysis

The fixed hearts and abdominal aortas were embedded in paraffin and sectioned. Step sections in the horizontal direction were made every 10 μm, to observe the histological changes in the coronary artery, aortic root, and abdominal aorta in detail. Haematoxylin and eosin (H&E) staining was performed to observe the inflammatory changes, by means of light microscopy. Verhoeff’s van Gieson (EVG) staining was used to investigate the vascular architecture. Immunohistochemical analysis was performed to detect the expression level of Bcl-2 using an anti-mouse Bcl-2 antibody (1:200, Cell Signalling Technology). The stained sections were photographed under a light microscope (Leica).

2.17 | Statistical analysis

All experiments were repeated at least three times to guarantee robust and unbiased results. Continuous variables are presented as mean ± standard deviation. Comparisons between two groups were performed using the two-tailed Student's t-test, while multi-group comparisons were carried out using one-way analysis of variance. Statistical significance was set at p ≤ 0.05; *p < 0.05, **p < 0.01, and ***p < 0.001. Statistical analyses were performed using SPSS version 19.0 (International Business Machines Corporation, USA), and data were visualized using Prism software version 9.0 (GraphPad Software, USA).

3 | RESULTS

3.1 | Melatonin alleviates CAWS-induced KD-like vasculitis in mice

Melatonin has been reported to have a protective effect on the vascular endothelium, and we hypothesized that it can also alleviate vasculitis in KD. To investigate the effect of melatonin on KD-related vasculitis, we first constructed a CAWS-induced vasculitis mouse model that resembles the typical vascular pathology of KD, as manifested by fever, weight loss, vascular inflammation, and splenomegaly, and then treated the mice with melatonin or PBS.
Melatonin inhibits vascular endothelial cell apoptosis. (A) Cell proliferation of HCAECs, as assessed using CCK-8 assay; the Mel+ group received 0.5 mM melatonin pre-treatment for 6 h, while the Mel- group did not. (B) After pre-treatment with or without 0.5 mM melatonin for 6 h, the HCAECs were cultured in ECM with H2O2 to induce cell apoptosis, following which apoptosis was analysed by means of Annexin V-FITC/PI double-staining and flow cytometry. (C) Mel+ group was pre-treated with 0.5 mM melatonin for 6 h, following which both the groups were stimulated with 20 ng/ml TNF-α for 12 h and relative mRNA expression levels of endothelial cell damage markers, including MMP-9, E-selectin, ICAM-1, and VCAM-1 were detected using RT-qPCR. (D) ELISA assay of the protein level of IL-6 in cell culture supernatants of HCAECs. (E) The Mel+ group was pre-treated with 0.5 mM melatonin for 6 h, following which both the groups were stimulated with 20 ng/ml TNF-α for 12 h and relative mRNA expression levels of anti-apoptotic genes Bcl2 and FLIP were detected using RT-qPCR. (F) Immunohistochemical staining of anti-apoptotic protein Bcl-2 in mice coronary arteries. Scale bar: 100 μm. (G) The levels of Bcl-2, cleaved-caspase-3, and cleaved-caspase-9 in HCAECs stimulated with TNF-α, with or without melatonin pre-treatment, were quantified using western blot. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001; ns, not significant. Bcl-2, B-cell lymphoma-2; CCK, cell counting kit; ECM, endothelial cell medium; FITC, fluorescein isothiocyanate; HCAEC, human coronary artery endothelial cell; ICAM-1, intercellular cell adhesion molecule-1; Mel, melatonin; MMP-9, matrix metalloproteinase 9; PI, propidium iodide; PLIP, FLICE inhibitory protein; TNF-α, tumour necrosis alpha; VCAM-1, vascular cell adhesion molecule-1.
FIGURE 3  Legend on next page.
according to the modelling timeline (Figure 1A). The results showed that the melatonin metabolite 6-sulfatoxymelatonin in the urine of mice in the melatonin-treated group was significantly higher than that in the other groups (Figure 1B). Melatonin treatment significantly relieved CAWS-induced fever and weight loss, as compared to PBS treatment (Figure 1C,D). Abdominal aortitis was alleviated after melatonin treatment (Figure 1E). H&E staining showed that severe inflammatory cell infiltration was induced by CAWS around the aortic root and coronary artery, which was significantly improved after melatonin treatment (Figure 1F). An improvement in splenomegaly was also observed after melatonin treatment (Figure 1G,H). EVG staining showed that the vascular elastic fibre injury of the aortic root was improved in the melatonin group (Figure 1I). In addition, ELISA assay showed remarkably decreased serum levels of TNF-α and IL-6 in the melatonin group, as compared to those in the CAWS group (Figure 1J).

3.2 | Melatonin inhibits vascular endothelial cell apoptosis

Next, we investigated whether melatonin plays a direct role in protecting vascular endothelial cells. To answer this question, we performed proliferation and apoptosis assays on HCAECs, with or without melatonin treatment. Subsequent results showed that cell proliferation was robustly promoted (Figure 2A), while apoptosis was significantly inhibited (Figure 2B) upon melatonin treatment. Vascular endothelial cell damage was also inhibited by melatonin, manifested as significantly decreased mRNA levels of endothelial cell damage markers, including matrix metalloproteinase 9 (MMP-9), E-selectin, intercellular cell adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) (Figure 2C). ELISA revealed a significant reduction in the protein level of IL-6 in the cell culture supernatant of HCAECs (Figure 2D). In addition, the mRNA levels of anti-apoptotic genes, including BCL2 and FLICE inhibitory protein (FLIP), were significantly increased after melatonin treatment (Figure 2E). Immunohistochemical staining showed that the anti-apoptotic protein Bcl2 was significantly reduced in the vascular walls of CAWS-treated mice, but was remarkably elevated after the administration of melatonin (Figure 2F). Consistently, western blot showed that the expression of Bcl-2 increased, while those of the pro-apoptotic proteins, including cleaved-caspase-3 and cleaved-caspase-9, decreased after melatonin treatment (Figure 2G). Collectively, these results suggested that melatonin can inhibit vascular endothelial cell apoptosis.

3.3 | Melatonin promotes autophagy via the phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signalling pathway in HCAECs

To explore the mechanism and target of melatonin’s protective effect on HCAECs, we performed RNA-seq on TNF-α-stimulated HCAECs, with or without melatonin pre-treatment. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that differentially expressed genes were mainly enriched in signalling pathways related to inflammation, cytokine interaction, autophagy, and apoptosis (Figure 3A). Genes related to autophagy were remarkably upregulated while those related to apoptosis and vascular endothelial cell damage were downregulated after melatonin treatment (Figure 3B). Among these differentially expressed genes, ATG3, an autophagy-related gene, attracted our attention. We further verified the sequencing data in HCAECs using RT-qPCR, and the results showed that the expression of ATG3 was indeed upregulated after melatonin treatment (Figure 3C). Western blot showed that TNF-α-stimulated HCAECs with melatonin pre-treatment exhibited a significantly increased ratio of LC3-II/LC3-I, which is indicative of autophagic activation, and a significant decrease in p62, whose expression level is negatively correlated with autophagy (Figure 3D), indicating that autolysosome formation was significantly increased in the melatonin group. Moreover, to determine whether melatonin has a robust autophagic flux-promoting effect on HCAECs under pathological conditions, HCAECs were infected with an adenoviral vector expressing mRFP-GFP-LC3, to detect the kinetics of autophagic flux. As expected, a greater number of free red dots were seen in the melatonin group, while a greater number of merged yellow dots were seen in the control group (Figure 3E), suggesting the activation of autophagic flux after melatonin treatment. Furthermore, to understand the signalling pathways involved in the regulation of autophagy by melatonin, we investigated alterations in the PI3K/AKT/mTOR pathway, which is negatively correlated with autophagy activation. Western blot showed that melatonin treatment substantially reduced the levels of p-AKT and p-mTOR (Figure 3F). Overall, these results support that melatonin promotes autophagy by inhibiting the PI3K/AKT/mTOR signalling pathway in HCAECs.
FIGURE 4  Legend on next page.
3.4 | MT/CREB/ATG3 pathway is responsible for melatonin-repressed apoptosis in HCAECs, in an autophagy-dependent manner

To explore the role of ATG3 in the protective effect of melatonin in HCAECs, we first transfected cells with an siRNA to silence ATG3. The CCK-8 assay showed a remarkable decrease in cell proliferation (Figure 4A), while flow cytometry showed a significant increase in cell apoptosis after ATG3 knockdown (Figure 4B). A notable increase in endothelial cell damage markers, including MMP-9, E-selectin, VCAM-1, and ICAM-1, was also observed after ATG3 knockdown (Figure 4C). As expected, western blot demonstrated that the expression of Bcl-2 was remarkably reduced in the ATG3-knockdown group, as compared to that in the control group (Figure 4D). To further confirm that melatonin has a protective effect on HCAECs by regulating ATG3 expression, we performed following experiments. A subsequent autophagic flux kinetics assay showed that the manifestation of more free red dots in the melatonin group was offset in the ATG3-knockdown group, which presented more merged yellow dots (Figures 4E and S2). In addition, ATG3-knockdown counteracted the stimulatory effect of melatonin on cell proliferation (Figure 4F), and the apoptosis-inhibitory effect of melatonin disappeared after ATG3 knockdown (Figure 4G). Generally, melatonin binds to its membrane receptors, MT1 and MT2, and initiates downstream signal transduction. To explore the signal transduction molecules that mediate the interaction between MT and ATG3, we analysed the transcription factors related to the GPCR pathway and predicted the transcription factors that can bind to the promoter region of ATG3. CREB appeared to be a candidate. The upregulation of ATG3 gene expression by melatonin disappeared in the presence of a CREB inhibitor (Figure 4H). To verify the interaction between CREB and the ATG3 promoter, we constructed vectors containing the ATG3 promoter sequence with the CREB binding site (Figure 4I). We then performed a luciferase assay to confirm the interaction of CREB and ATG3 promoter, and the results showed that the luciferase activity in the group co-transfected with plasmids carrying CREB-CDS and ATG3 promoter sequences was notably increased, compared to that in the group co-transfected with vectors carrying CREB-CDS and a blank vector without the ATG3 promoter sequence (Figure 4J). Taken together, these findings indicated that after melatonin binds to its receptors MT1/2, the transcription factor CREB is initiated and it further upregulates the expression of ATG3, which is responsible for melatonin-repressed apoptosis in HCAECs, in an autophagy-dependent manner.

3.5 | Atg3 deficiency blocks the protective effects of melatonin in the KD mouse model

Next, to determine whether Atg3 is responsible for the protective effect of melatonin in CAWS-induced KD vasculitis, we injected a lentivirus carrying shRNA into mice, to silence Atg3, and then administered melatonin according to the modelling timeline (Figure 5A). Upon injecting shRNA, there was a remarkable reduction in the Atg3 expression in the heart tissues of KD mice (Figure 5B). Mice showed more severe fever and weight loss in the absence of Atg3 (Figure 5C,D). The previously remitted abdominal aortitis reappeared after silencing of Atg3 (Figure 5E). H&E staining showed that the severe inflammatory cell infiltration around the aortic root and coronary artery that was previously improved by melatonin treatment was observed again after silencing of Atg3 (Figure 5F). Recurrence of splenomegaly was also observed after silencing of Atg3 (Figure 5G,H). Immunohistochemistry revealed that there was a decrease in the expression of Bcl-2 in the cardiovascular tissues of KD mice in the Atg3-silenced group (Figure 5I). ELISA showed that serum levels of TNF-α and IL-6 were elevated after silencing of Atg3 in KD mice (Figure 5J). Taken together, these findings indicated that silencing of Atg3 blocked the protective effects of melatonin in KD mice in vivo.

3.6 | Melatonin inhibits macrophage-mediated immunopathological damage of vascular endothelial cells in patients with KD

Given that KD-related vasculitis is a crosstalk between vascular endothelial cells and immune cells, we questioned whether melatonin may also inhibit inflammatory responses mediated by immune...
FIGURE 5  Legend on next page.
cells in KD-related vasculitis. Previous studies have demonstrated that during the pathogenesis of KD, macrophages can release inflammatory cytokines to mediate damage to vascular endothelial cells.\textsuperscript{32,34,35} A recent single cell sequencing study revealed that monocytes are the main source of differentially expressed genes, and pro-inflammatory genes such as IL-1β and TNF-α are significantly upregulated in PBMCs of KD patients, suggesting a pivotal role of monocytes/macrophages in KD vasculitis.\textsuperscript{36} Therefore, we investigated the effects of melatonin on macrophage-mediated inflammation. Subsequent RT-qPCR results demonstrated remarkably decreased mRNA levels of IL-6, IL-1β, and TNF-α, in LPS-stimulated human THP1-derived macrophages pre-treated with melatonin (Figure 6A). Consistently, ELISA analysis showed a decreased protein level of IL-6 in the culture supernatant of melatonin-treated THP1 cells (Figure 6B). TNF-α is the one of the leading cytokines mediating KD vasculitis, in order to better mimic the activation of macrophages in KD, we also investigated the anti-inflammatory role of melatonin in TNF-α-stimulated human THP1-derived macrophages. Consistent with previous results, subsequent RT-qPCR results demonstrated remarkably decreased mRNA levels of IL-6, IL-1β, and TNF-α (Figure 6C). To consolidate our findings, we separated PBMCs from KD patients and induced them into macrophages using rhM-CSF. RT-qPCR results showed that the mRNA levels of TNF-α, IL-1β, and IL-6 were lower in the melatonin-treated human PBMC-derived macrophages than in the PBS-treated human macrophages, which was consistent with the results observed in THP1-derived macrophages (Figure 6D). Next, to investigate whether melatonin alleviated the HCAEC damage by reducing the levels of pro-inflammatory cytokines secreted by macrophages, we established an in vitro coculture system (Figure 6E). Intriguingly, HCAECs cultured with the supernatant of LPS-stimulated THP1-derived macrophages pre-treated with melatonin exhibited repressed apoptosis (Figure 6F) and enhanced proliferation (Figure 6G). To further investigate the role of melatonin in the interaction between macrophages and vascular endothelial cells, we explored the effect of melatonin on the chemotaxis of HCAECs to macrophages, transwell assay showed that there was a significant decrease in the number of macrophages migrating towards HCAECs in the group pre-treated with melatonin (Figure 6H). These data highlight the critical role of melatonin in regulating the crosstalk between HCAECs and macrophages in KD-related vasculitis.

\section*{4 Discussion}

In the present study, we found that melatonin alleviated KD-related vascular endothelial cell damage both in vitro and in vivo, by activating the melatonin/MT/CREB pathway and subsequent ATG3 expression, thereby suppressing vascular endothelial cell apoptosis in an autophagy-dependent manner. Additionally, melatonin reduced the production of pro-inflammatory cytokines released by macrophages and indirectly reduced the immunopathological damage to vascular endothelial cells (Figure 7). Taken together, our findings revealed the potential of melatonin as a therapeutic alternative for KD.

CREB is a transcription factor that plays a crucial role in regulating cell proliferation, apoptosis, and autophagy, by inducing the expression of related genes. Melatonin exerts its protective effects by regulating CREB in a broad spectrum of diseases. Melatonin overcomes the disrupted brain energy homeostasis and boosts neuroinflammation, thereby protecting against brain damage, by regulating the phospho-5\textsuperscript{AMP}A activated protein kinase/CREB signalling pathways in traumatic brain injury.\textsuperscript{37} Another study revealed that melatonin improved cognitive and mood impairments by modulating oxidative stress, NLRP3 inflammasomes, and the BDNF (brain-derived neurotrophic factor)/ERK (extracellular signal-regulated kinase)/CREB pathway in a rat model of chronic Gulf War Illness.\textsuperscript{38} The interaction between CREB and autophagy also plays a pivotal role in the occurrence and development of diseases.\textsuperscript{39} CREB mediates the expression of autophagy-related genes.\textsuperscript{40} Our present study identified a crucial role of CREB in the maintenance of the autophagy-promoting effect of melatonin. Melatonin binds to MT1/2 receptors and activates CREB, to upregulate the target gene ATG3, thereby exerting an anti-apoptotic effect in HCAECs, in an autophagy-dependent manner. These findings provide a novel mechanism for the autophagy-modulating effects of melatonin in KD.

Splenomegaly was an obvious feature observed in CAWS-induced murine vasculitis in the present study, but it has not been described in detail in previous reports. Splenomegaly is observed in clinical KD patients and is associated with hyper-activated inflammatory responses manifested by excessive production of a wide array of inflammatory cytokines in KD-macrophage activation syndrome (MAS).\textsuperscript{41} Considering the critical role of splenomegaly in the vascular pathology of KD, we believe that the CAWS-induced murine vasculitis model could simulate KD-related vascular pathology.
MAS is a hyper-activated inflammatory state characterized by the activation and expansion of T lymphocytes and hemophagocytic macrophages that eventually leads to a series of clinical manifestations, including persistent fever, cytopenia, liver dysfunction, coagulopathy, and extreme hyperferritinemia.\(^\text{42-44}\) Han et al. showed that the existence of MAS should be considered when a KD patient shows
persistent fever, splenomegaly, cytopenia, hyperferritinemia, or IVIG resistance. Therefore, relief of the hyper-inflammatory state of MAS may contribute substantially to the reduced burden of KD, and melatonin could be used as an agent for that purpose, since it regulates macrophage-mediated inflammation. In the present study, we observed that melatonin significantly suppressed the levels of pro-inflammatory cytokines such as IL-1β and IL-6 in THP1-derived macrophages, as well as, human PBMC-derived macrophages in KD patients. In addition, we demonstrated that melatonin alleviated vascular endothelial cell damage partly by modulating macrophage activation, suggesting that macrophages may be a therapeutic target for KD-related vascular damage.

In summary, our study provides theoretical foundation for the use of melatonin as an additional therapy to further reduce the incidence of CAA in KD, and presents a new concept that an imbalance in homeostasis of the autophagy-apoptosis axis might be the underlying pathological mechanism of KD. In addition, ATG3 and autophagy are the other possible therapeutic targets for KD, and by virtue of several biological or physical materials, ATG3- or autophagy-based treatments may be achieved in future. Our study also provides evidence that suppressing macrophage activation is a strategy for the treatment of KD. The activation of macrophages is directly related to the occurrence, development, and prognosis of a variety of inflammatory diseases, such as juvenile idiopathic arthritis, inflammatory bowel disease, and atherosclerosis. Therefore, our findings would be of great interest to a broader scientific community.

4.1 | Limitations of this study

One limitation of this study is that we recruited only 16 patient samples, and this small sample size limited the accuracy of assessing the anti-inflammatory effect of melatonin in PBMC-derived macrophages from KD patients. Another limitation of the study is that it does not explore the detailed mechanism of the anti-inflammatory effect of melatonin in macrophages.

AUTHOR CONTRIBUTIONS
Yuanzheng Zheng, Xiao Han, and Yonghao Gui contributed to the conception and design of the study. Yuanzheng Zheng and Saihua Huang contributed to data collection. Jialing Zhang, Jia Hou, Fang Wu, and Wenji Wang performed the statistical analyses. Yuanzheng Zheng wrote the first draft of the manuscript. Saihua Huang, Xiao Han, and Jialing Zhang wrote sections of the manuscript. All authors contributed to the manuscript revision and approved the submitted version.

ACKNOWLEDGEMENTS
This work was supported by grants from the Construction of High-level Universities in Shanghai, Child Development and Health Inter-Section Institute (2019DGJFYJK01, 2020DGJFYJK01, and 2021DGJFYJK01), National Natural Science Foundation of China (81900751 to X.H.), Shanghai Committee of Science and Technology (20ZR1408300 to X.H.), and Fudan University Original project (IDF156012/001 to X.H.).
CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

DATA AVAILABILITY STATEMENT
The data referred to in this study have been deposited in Gene Expression Omnibus database, with the accession number GSE183359.

REFERENCES
1. Lin MT, Wu MH. The global epidemiology of Kawasaki disease: review and future perspectives. Glob Cardiol Sci Pract. 2017;2017(3): e201720.
2. Xie LP, Yan WL, Huang M, et al. Epidemiologic features of Kawasaki disease in shanghai from 2013 through 2017. J Epidemiol. 2020;30(10):429-435.
3. Ae R, Makino N, Kosami K, Kuvabara M, Matsubara Y, Nakamura Y. Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: the nationwide survey in Japan, 2017–2018. J Pediatr. 2020;225:23-29.e2.
4. Singh S, Vignesh P, Burgner D. The epidemiology of Kawasaki disease: a global update. Arch Dis Child. 2015;100(11):1084-1088.
5. Stock AT, Jarra HA, Hansen JA, Wicks IP. TNF and IL-1 play essential but temporarily distinct roles in driving cardiac inflammation in a murine model of Kawasaki disease. J Immunol. 2019;202(11):3151-3160.
6. Mccrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999.
7. Yoshikane Y, Okuma Y, Miyamoto T, et al. Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study. Pediatr Rheumatol Online J. 2021;19(1):82.
8. Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017;1:CD011188.
9. Stein RM, Kang HJ, McCorvy JD, et al. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms. Nature. 2020;579(7390):609-614.
10. Xia Y, Chen S, Zeng S, et al. Melatonin in macrophage biology: current understanding and future perspectives. J Pineal Res. 2019;66(2):e12547.
11. Xia L, Sun C, Zhu H, et al. Melatonin protects against thoracic aortic aneurysm and dissection through SIRT1-dependent regulation of oxidative stress and vascular smooth muscle cell loss. J Pineal Res. 2020;69(1):e12661.
12. Liu PL, Chang AC, Lai JL, et al. Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases. Oncogene. 2021;40(8):1503-1515.
13. Posa L, Lopez-Canul M, Rullo L, et al. Noceceptive responses in melatonin MT2 receptor knockout mice compared to MT1 and double MT1/MT2 receptor knockout mice. J Pineal Res. 2020;69(3):e12671.
14. Zhang Y, Wang Y, Xu J, et al. Melatonin attenuates myocardial ischemia-reperfusion injury via improving mitochondrial fusion/mitophagy and activating the AMPK-OPA1 signaling pathways. J Pineal Res. 2019;66(2):e12542.
15. Zhao Z, Wang X, Zhang R, et al. Melatonin attenuates smoking-induced atherosclerosis by activating the Nrf2 pathway via NLRP3 inflammasomes in endothelial cells. Aging. 2021;13(8):11363-11380.
16. MacLean MR. Melatonin: shining some light on pulmonary hypertension. Cardiovasc Res. 2020;116(13):2036-2037.
17. Baltatu OC, Amaral FG, Campos LA, Cipolla-Neto J. Melatonin, mitochondria and hypertension. Cell Mol Life Sci. 2017;74(21):3955-3964.
18. Wang Q, Liu X. The dual functions of alpha-tubulin acetylation in cellular apoptosis and autophagy induced by taxanes:pimycin in lung cancer cells. Cancer Cell Int. 2020;20:369.
19. Levine B, Ranganathan R. Autophagy: snapshot of the network. Nature. 2010;466(7302):38-40.
20. Hassanpour M, Rahbarhaghi R, Nouri M, Aghamohammadzadeh N, Safaei N, Ahmadi M. Role of autophagy in atherosclerosis: foe or friend? J Inflamm (Lond). 2019;16:8.
21. Marek-Iannucci S, Ozdemir AB, Moreira D, et al. Autophagy-mitophagy induction attenuates cardiovascular inflammation in a murine model of Kawasaki disease vasculitis. JCI Insight. 2021;6(18):e151981.
22. Huang FC, Huang YH, Kuo HC, Li SC. Identifying downregulation of autophagy markers in Kawasaki disease. Children (Basel). 2020;7(10):166.
23. Huang FC, Kuo HC, Huang YH, Yu HR, Li SC, Kuo HC. Anti-inflammatory effect of resveratrol in human coronary arterial endothelial cells via induction of autophagy: implication for the treatment of Kawasaki disease. BMC Pharmacol Toxicol. 2017;18(1):3.
24. Marinho G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2014;15(2):81-94.
25. Fernández AF, Sebti S, Wei Y, et al. Disruption of the bcln 1-BCL2 autophagy regulatory complex promotes longevity in mice. Nature. 2018;558(7708):136-140.
26. Vázquez CL, Colombo MI. Beclin 1 modulates the anti-apoptotic activity of Bcl-2: insights from a pathogen infection system. Autophagy. 2010;6(1):177-178.
27. Jia C, Zhuo Y, Zhang S, et al. IL-37b alleviates endothelial cell apoptosis and inflammation in Kawasaki disease through IL-1R8 pathway. Cell Death Dis. 2021;12(6):575.
28. Yahata T, Hamaoka K. Oxidative stress and Kawasaki disease: how is oxidative stress involved from the acute stage to the chronic stage? Rheumatol (Oxford). 2017;56(1):6-13.
29. Ramos E, Patiño P, Reiter RJ, Gil-Martín E, L´opez-Muñoz F, Romero A. Melatonin: a hypothesis for Kawasaki disease treatment. Med Hypotheses. 2018;119:6-10.
30. JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease. JCS 2013. Digest version. Circ J. 2014;78(10):2521-2562.
31. Fukazawa R, Kobayashi J, Ayasawa M, et al.; on behalf of the Japanese Circulation Society Joint Working Group. JCS/JSC 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J. 2020;84(8):1348-1407.
32. Stock AT, Hansen JA, Sleeman MA, McKenzie BS, Wicks IP. GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. J Exp Med. 2016;213(10):1983-1998.
33. Novai Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models. Rev Med Hospit. 2020;16(7):391-405.
34. Pilania RK, Jindal AK, Johnson N, et al. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in Northwest India. Rheumatol (Oxford). 2021; 60(7):3413-3419.
35. Han SB, Lee SY. Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches. World J Pediatr. 2020;16(6):556-574.
36. Wang Z, Xie L, Ding G, et al. Single-cell RNA sequencing of peripheral blood mononuclear cells from acute Kawasaki disease patients. Nat Commun. 2021;12(1):5444.
37. Rehman SU, Ikram M, Ullah N, et al. Neurological enhancement effects of melatonin against brain injury-induced oxidative stress,
neuroinflammation, and neurodegeneration via AMPK/CREB signaling. Cells. 2019;8(7):760.

38. Madhu LN, Kodali M, Attaluri S, et al. Melatonin improves brain function in a model of chronic gulf war illness with modulation of oxidative stress, NLRP3 inflammasomes, and BDNF-ERK-CREB pathway in the hippocampus. Redox Biol. 2021;43:101973.

39. Choi HJ, Yeon MH, Jun HS. Schisandrae chinensis Fructus extract ameliorates muscle atrophy in streptozotocin-induced diabetic mice by downregulation of the CREB-KLF15 and autophagy-lysosomal pathways. Cells. 2021;10(9):2283.

40. Pan Y, Zhou G, Li W, et al. Excitation-transcription coupling via synapto-nuclear signaling triggers autophagy for synaptic turnover and long-lasting synaptic depression. Autophagy. 2021;17(11):3887-3888.

41. Kang DW, Kim SH. Clinical aspects of splenomegaly as a possible predictive factor of coronary artery changes in Kawasaki disease. Cardiol Young. 2019;29(3):297-302.

42. Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129(5):630-632.

43. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine a in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129(5):750-754.

44. Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259-268.

45. Xu Y, Cui K, Li J, et al. Melatonin attenuates choroidal neovascularization by regulating macrophage/microglia polarization via inhibition of RhoA/ROCK signaling pathway. J Pineal Res. 2020;69(1):e12660.

46. Liu W, Yu M, Xie D, et al. Melatonin-stimulated MSC-derived exosomes improve diabetic wound healing through regulating macrophage M1 and M2 polarization by targeting the PTEN/AKT pathway. Stem Cell Res Ther. 2020;11(1):259.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Zheng Y, Huang S, Zhang J, et al. Melatonin alleviates vascular endothelial cell damage by regulating an autophagy-apoptosis axis in Kawasaki disease. Cell Prolif. 2022;55(6):e13251. doi:10.1111/cpr.13251